The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 16, 2021

Filed:

Feb. 12, 2014
Applicants:

The Research Foundation for the State University of New York, Albany, NY (US);

Icahn School of Medicine AT Mount Sinai, New York, NY (US);

Inventors:

Ioannis Danias, Staten Island, NY (US);

Oscar A. Candia, New Rochelle, NY (US);

Rosana Gerometta, Corrientes, AR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/49 (2006.01); A61K 38/20 (2006.01); C12N 15/86 (2006.01); A61K 31/12 (2006.01); A61K 31/09 (2006.01); A61K 31/366 (2006.01); A61K 31/427 (2006.01); A61K 31/7088 (2006.01); C12N 7/00 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/49 (2013.01); A61K 31/09 (2013.01); A61K 31/12 (2013.01); A61K 31/366 (2013.01); A61K 31/427 (2013.01); A61K 31/7088 (2013.01); A61K 38/204 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 48/00 (2013.01); C12N 2710/10341 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15071 (2013.01); C12N 2750/00043 (2013.01); C12N 2750/00071 (2013.01); C12Y 304/21068 (2013.01);
Abstract

Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.


Find Patent Forward Citations

Loading…